Pasar al contenido principal

UTILIZACION DEL VIRUS DE LA FIEBRE DEL VALLE DEL RIFT COMO VECTOR VACUNAL: MEJORA RACIONAL DE SU SEGURIDAD, ESTABILIDAD Y TRAZABILIDAD

AGL2017-83226-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA - CSIC

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Using RVFV as a Vector Platform for the Expression of Ruminant Disease Antigens, Methods and protocols

  • Moreno, Sandra
  • Borrego, Belén
  • Brun Torres, Alejandro
209–225 pp, Live attenuated viruses remain as vaccine agents with unparalleled performance in terms of duration, magnitude, and breadth of induced immune responses. As the yellow fever-attenuated vaccine strain Y17D, attenuated Rift Valley fever virus shares features suitable to be used as a viral vector for heterologous antigen expression and bivalent vaccine development. Current reverse genetics technology showed the successful rescue of RVFV carrying foreign antigens with little immunogenicity loss in experimental animal models. We show here the basic experimental protocol to achieve the expression of candidate vaccine antigens from other important diseases of ruminants using RVFV as a vector platform as well as preliminary steps for the characterization of immunogenicity in vivo., This work was funded by grants AGL2017-83226R and S2018/BAA-4370 from Ministerio de Ciencia and Comunidad de Madrid respectively., Peer reviewed